Clinical Significance of Anticardiolipin Antibodies in Patients with Systemic Sclerosis

Picillo, U; Migliaresi, S.; Marcialis, M. R.; Ferruzzi, Anna Maria; Tirri, G

doi:10.3109/08916939508993333

Cited by 28 publications

(20 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some authors reported an association of anticardiolipin antibodies with increased disease severity, particularly as manifested by pulmonary hypertension and endothelial injury [146][147][148][149], but these findings were not corroborated by all studies [150,151]. Antiphospholipid syndrome in association with SSc has been reported rarely, most recently in association with pregnancy loss [152][153][154].…”

Section: Matrix Metalloproteinasesmentioning

confidence: 96%

Update on autoantibodies in systemic sclerosis

Walker

Fritzler

2007

Current Opinion in Rheumatology

View full text Add to dashboard Cite

show abstract

Section: Matrix Metalloproteinasesmentioning

confidence: 96%

Update on autoantibodies in systemic sclerosis

Walker

Fritzler

2007

Current Opinion in Rheumatology

View full text Add to dashboard Cite

show abstract

“…The prevalence data of aPL in SSc range from 20 to 25 % [42,71]. The presence of aPL is associated with increased abortions in SSc patients and higher incidence of thrombosis and pulmonary hypertension [72,73].…”

Section: Anti-phospholipid/anti-cardiolipin Antibodies (Apl Acl)mentioning

confidence: 99%

Autoantikörper bei systemischer Sklerodermie: Bedeutung für Diagnostik, Prognose und Pathogenese

Grassegger¹,

Pohla‐Gubo

Frauscher

et al. 2008

Wien Med Wochenschr

View full text Add to dashboard Cite

Systemic sclerosis is a generalized autoimmune connective tissue disease of unknown aetiology. Profound vascular and immunological dysregulations result in tissue fibrosis affecting the skin and internal organs. Currently, two main clinical subtypes are distinguished, i.e. limited and diffuse cutaneous systemic sclerosis, which differ significantly in the clinical course and prognosis. Autoantibodies against topoisomerase (Scl-70), centromere-associated proteins, and nucleolar antigens are important for the diagnosis of the disease and give clues for its clinical manifestations and prognosis (prognostic autoantibodies). For most of these antibodies, however, the role in pathogenesis is not established. Anti-centromere antibodies are associated with limited cutaneous involvement and risk for pulmonary hypertension, whereas anti-topoisomerase I is associated with diffuse progressive disease and severe interstitial lung disease. Anti-Th/To positivity is associated with limited skin involvement but a high risk for severe internal organ involvement (Kidneys, PAH, Lung fibrosis). Anti-RNA polymerase I/III antibodies are associated with a high risk for renal involvement. Autoantibodies against the PDGF receptor and fibrillin-1 seem to play important roles in the pathogenetic process of systemic sclerosis.

show abstract

“…In two studies, aCL were also associated with myocardial ischemia or necrosis [100], although not with the presence of valvular lesions or diastolic dysfunction.…”

Section: Other Autoantibodiesmentioning

confidence: 99%

Untitled

Reveille

2003

Arthritis Res Ther

191

View full text Add to dashboard Cite

80ACA = anti-centromere antibodies; aCL = anticardiolipin antibodies; AFA = antifibrillarin/anti-U3-RNP; ANA = anti-nuclear antibodies; ANCA = anti-neutrophil cytoplasmic antibodies; ANoA = anti-nucleolar antibodies; anti-RNAP = anti-RNA-polymerase antibodies; anti-Sm = anti-Smith antibodies; aPL = antiphospholipid antibodies; β 2 gp I = β 2 glycoprotein I antibodies; CENP = centromeric nucleoprotein; CIE = counterimmunoelectrophoresis; CREST = a variant of SSc defined by the presence of calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangectasia; CTD = connective tissue diseases; dcSSc = diffuse cutaneous systemic sclerosis; DL CO = diffusion capacity for carbon monoxide; DM = dermatomyositis; ELISA = enzyme-linked immunosorbent assay; FVC = forced vital capacity; HLA = human leukocyte antigen; IB = immunoblotting; ID = immunodiffusion; IIF = indirect immunofluorescence; IP = immunoprecipitation; lcSSc = limited cutaneous systemic sclerosis; MCTD = mixed connective tissue disease; PFT = pulmonary function tests; PM = polymyositis; PM/SSc = myositis/scleroderma overlap; RLD = restrictive lung disease; RNP = ribonucleoprotein; SLE = systemic lupus erythematosus; snRNP = small nuclear RNP; SSc = systemic sclerosis. Arthritis Research & Therapy Vol 5 No 2 Ho and Reveille IntroductionSystemic sclerosis (scleroderma or SSc) is a heterogeneous disorder characterized by autoantibody subsets, which in turn have their own clinical associations. Much controversy resides in whether these autoantibodies contribute directly to the pathology seen in SSc or whether they are merely epiphenomena of the underlying disease process. Nevertheless, various autoantibodies found in patients with SSc carry significant value in diagnosis and in predicting clinical outcomes (Fig. 1). The autoantibodies classically associated with SSc include anti-centromere antibodies (ACA) and anti-Scl-70 (otherwise known as antitopoisomerase I or anti-topo I). In addition to these is the less commonly occurring anti-nucleolar antibody (ANoA) system, which comprises a mutually exclusive heterogeneous group of autoantibodies that produce nucleolar stain- AbstractScleroderma (systemic sclerosis) is associated with several autoantibodies, each of which is useful in the diagnosis of affected patients and in determining their prognosis. Anti-centromere antibodies (ACA) and anti-Scl-70 antibodies are very useful in distinguishing patients with systemic sclerosis (SSc) from healthy controls, from patients with other connective tissue disease, and from unaffected family members. Whereas ACA often predict a limited skin involvement and the absence of pulmonary involvement, the presence of anti-Scl-70 antibodies increases the risk for diffuse skin involvement and scleroderma lung disease. Anti-fibrillarin autoantibodies (which share significant serologic overlap with anti-U3-ribonucleoprotein antibodies) and anti-RNA-polymerase autoantibodies occur less frequently and are also predictive of diffuse skin involvement and systemic dise...

show abstract

Clinical Significance of Anticardiolipin Antibodies in Patients with Systemic Sclerosis

Cited by 28 publications

References 28 publications

Update on autoantibodies in systemic sclerosis

Update on autoantibodies in systemic sclerosis

Autoantikörper bei systemischer Sklerodermie: Bedeutung für Diagnostik, Prognose und Pathogenese

Untitled

Contact Info

Product

Resources

About